Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001470831-26-000260 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-12 | 2026-03-10 | BBIO | Valantine Hannah | Dir | M - OptEx | $27.36 | +8,671 | 16.1K | +116% | +$237.2K |
| D | 2026-03-12 | 2026-03-10 | BBIO | Valantine Hannah | Dir | S - Sale+OE | $72.00 | -8,671 | 7,465 | -54% | -$624.3K |
| D | 2026-03-12 | 2026-03-10 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -8,671 | 17.3K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-10 | M | A | 8,671 | $27.36 | 16,136 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-10 | S | D | 8,671 | $72.00 | 7,465 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-03-10 | M | D | 8,671 | $0.00 | 17,343 | D | $27.36 · — to 2034-06-20 | 8,671 Common Stock | (F2) One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. |